Key Highlights

  • Booking Holdings (NASDAQ:BKNG) retired USD 2.1 billion of its stock in the third quarter and USD 9.9 billion across nine months, even though the shares sit near a 52-week low.
  • Arch Capital spent roughly USD 1.4 billion on repurchases during the quarter, about 109% of net income, cutting diluted shares to 341.4 million from 376.1 million.
  • Regeneron bought back USD 2.3 billion over nine months, Allstate returned close to USD 1.5 billion in the quarter, and Elevance still has about USD 5.0 billion of authorization available.
  • Four of the five trade near their 52-week highs, while Booking is purchasing heavily into a stock that has surrendered its post-earnings gain.

1. Booking Holdings (NASDAQ:BKNG)

Booking Holdings (NASDAQ:BKNG) leads on pace of capital return. The online travel firm bought back USD 2.1 billion of shares in the third quarter and USD 9.9 billion across nine months, trimming the diluted share count roughly 7.5% to 753 million, with USD 12.4 billion of authorization still in place. The quarterly Dividend of USD 0.42 becomes payable December 31. Buybacks are happening at lower prices. The shares had surged roughly 10% after the November 3 results, yet the slide since has wiped out that move, leaving the stock at USD 154.46 on November 17, about 5.6% above its 52-week low. Operating results were sound: room nights rose 7% to 345 million, gross bookings grew 10% to USD 54.5 billion, and adjusted EPS climbed 17% to USD 4.66. The concern lies in the outlook. Fourth quarter room night growth is guided to 1% to 3% and gross bookings growth to 2% to 4%, reflecting softer travel Demand late in the quarter, and investors are also weighing how artificial intelligence may change traveler search habits. Free Cash Flow dropped 22% during the quarter, a figure some investors weigh against the scale of the buyback. Booking ranks first because no other name in this group retires stock as quickly, and doing so near a low amplifies the per share gain if demand steadies.

2. Arch Capital (NASDAQ:ACGL)

Arch Capital (NASDAQ:ACGL) comes second, with the heaviest buyback relative to earnings. The insurer bought back roughly USD 1.4 billion of shares in the third quarter, about 109% of Net Income and nearly double the USD 732 million of a year earlier, lifting its year to date total to around USD 3.4 billion. Weighted diluted shares declined to 341.4 million from 376.1 million, while common shares outstanding stood at 326.4 million versus 367.3 million a year before. Management noted roughly USD 100 million was repurchased in October, a pace constrained by a trading blackout. Operating Cash Flow of USD 1,759 million during the quarter supported the pace. Earnings are flat to slightly lower. After-tax operating EPS came in at USD 2.67 versus USD 2.77, operating Return on Equity was 16.0%, and Reinsurance premiums dropped 8.0% as the company let Business run off in softer lines. Chief executive Nicolas Papadopoulo stated the company will not pursue growth for its own sake. Book Value per share of USD 67.90 sat about 8.9% higher than a year earlier. The shares declined 1.51% to USD 109.22 on November 17, roughly 4% under their high. Arch ranks second because repurchasing stock instead of writing weaker business protects returns, although the remaining authorization was not disclosed.

3. Regeneron (NASDAQ:REGN)

Regeneron (NASDAQ:REGN) claims third, with its buyback supported by the group's most substantial cash pile. Over the first nine months the biotech purchased USD 2.3 billion of its stock and still holds about USD 2.2 billion of authorization. Cash and marketable securities total approximately USD 18.9 billion, compared with roughly USD 2.0 billion of long term debt, and a broadened Sanofi collaboration is set to contribute USD 1.0 billion upfront in the fourth quarter. Profit expansion gives the buyback a firm base. Third quarter Revenue grew 36% to USD 5.116 billion, while non-GAAP EPS surged 70% to USD 20.07, aided by record sales of Dupixent, EYLEA HD and Libtayo. Leadership raised its product gross Margin outlook to around 86% and trimmed expense guidance. A dividend is paid as well. On November 17 the European Commission endorsed an alternative Libtayo dosing schedule, and the stock rose 0.58% to USD 957.76, about 3.4% under its high. Regeneron places third because its buyback looks modest against Market Value next to Booking or Arch, though its Balance Sheet ensures repurchases do not crowd out research spending or dealmaking. Investor conference appearances on December 1 and December 2 may bring capital allocation news.

4. Allstate (NYSE:ALL)

Allstate (NYSE:ALL) finishes fourth, with large payouts tied to a limited authorization. The insurer returned close to USD 1.5 billion to holders in the third quarter through buybacks and dividends, and roughly USD 1.3 billion is unused from a USD 4.0 billion repurchase program begun in February 2026. That balance represents about another quarter at the present rate. On November 12 the company declared a quarterly dividend of USD 1.08, payable January 4, 2027. The operating business is able to fund it. Adjusted EPS hit USD 9.76 even with USD 1.65 billion of catastrophe losses, the underlying combined ratio came in at 80.5, and trailing adjusted return on equity reached 39.7%. Book value per share rose 25.3% to USD 120.23, while policies in force expanded 3.9% to 217.6 million. Nine month Underwriting income climbed 47.5% to USD 6.7 billion, leaving space to absorb a storm heavy quarter without changing capital plans. The shares held flat at USD 270.43 on November 17, roughly 3.8% under their high. Allstate ranks fourth because the market will look at whether repurchases keep their pace once the present authorization is exhausted, with fourth quarter storm losses potentially influencing that call.

5. Elevance Health (NYSE:ELV)

Elevance Health (NYSE:ELV) takes fifth, with consistent buybacks and ample capacity to continue. The health insurer repurchased about 0.8 million shares for USD 330 million in the third quarter, averaging USD 398.75, and roughly USD 1.69 billion over nine months, leaving close to USD 5.0 billion of authorization. The quarterly dividend of USD 1.72 is due December 18. Cash and investments at the Parent Company stood at about USD 2.4 billion on September 30. Earnings are on an upswing. Third quarter adjusted EPS advanced 15.9% to USD 6.99, the benefit expense ratio contracted 70 basis points to 90.6%, and 2026 operating cash flow guidance moved up to at least USD 6.5 billion. Adjusted EPS guidance was raised to at least USD 29.00, and management is targeting growth of at least 12% in 2027 off a base of at least USD 26.75. Shares trade above the third quarter buyback price, sitting at USD 433.93 on November 17 after a 2.77% drop linked to a federal proposal to widen Medicare Advantage audits. Elevance ranks fifth because its quarterly buyback is the smallest in the group, yet the sizable remaining authorization offers the most flexibility to accelerate purchases if policy concerns press the stock lower.

Where Things Stand

Within this top 5 buyback group, Booking Holdings returns capital most quickly, with USD 9.9 billion repurchased over nine months and a share count 7.5% smaller. Arch Capital is repurchasing more than it earns, Regeneron has the largest cash buffer, Allstate is nearing the close of its authorization, and Elevance has the greatest headroom.